Cargando…

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial

The bevacizumab (bev)/olaparib (ola) maintenance regimen was approved for BRCA1/2-mutated (BRCAmut) and Homologous Recombination Deficient (HRD) high-grade Advanced Ovarian Cancer (AOC) first line setting, based on a significantly improved progression-free survival (PFS) compared to bev alone in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Callens, Celine, Rodrigues, Manuel, Briaux, Adrien, Frouin, Eleonore, Eeckhoutte, Alexandre, Pujade-Lauraine, Eric, Renault, Victor, Stoppa-Lyonnet, Dominique, Bieche, Ivan, Bataillon, Guillaume, Karayan-Tapon, Lucie, Rochelle, Tristan, Heitz, Florian, Cecere, Sabrina Chiara, Pérez, Maria Jesús Rubio, Grimm, Christoph, Nøttrup, Trine Jakobi, Colombo, Nicoletta, Vergote, Ignace, Yonemori, Kan, Ray-Coquard, Isabelle, Stern, Marc-Henri, Popova, Tatiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673712/ https://www.ncbi.nlm.nih.gov/pubmed/37945748 http://dx.doi.org/10.1038/s41388-023-02839-8

Ejemplares similares

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
por: Pujade-Lauraine, Eric, et al.
Publicado: (2023)

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
por: Fujiwara, Keiichi, et al.
Publicado: (2021)

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2023)

Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions
por: Herzog, Thomas J, et al.
Publicado: (2023)

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
por: Monk, Bradley J., et al.
Publicado: (2020)

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
por: Grisham, Rachel N., et al.
Publicado: (2023)

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
por: Matulonis, Ursula A., et al.
Publicado: (2019)

A Conversation With Paola D’Angelo
por: Patel, Prachi
Publicado: (2018)

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
por: del Campo, Josep M., et al.
Publicado: (2019)

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
por: O’Cearbhaill, Roisin E., et al.
Publicado: (2022)

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
por: Monk, Bradley J., et al.
Publicado: (2022)

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
por: Moore, Kathleen N., et al.
Publicado: (2021)

Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects
por: Mirza, Mansoor Raza, et al.
Publicado: (2022)

First person – Paola Lepanto and Florencia Levin-Ferreyra
Publicado: (2021)

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
por: Ray-Coquard, Isabelle, et al.
Publicado: (2019)

Preliminary Study of the Mural Paintings of Sotterra Church in Paola (Cosenza, Italy)
por: Ricca, Michela, et al.
Publicado: (2022)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Culicoides paolae and C. circumscriptus as potential vectors of avian haemosporidians in an arid ecosystem
por: Veiga, Jesús, et al.
Publicado: (2018)

ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing
por: Eeckhoutte, Alexandre, et al.
Publicado: (2020)

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels
por: Rondeau, S, et al.
Publicado: (2015)

Paola Durante, víctima de la Procuraduría del Distrito Federal : historia de una infamia /
por: Masso, Ernesto
Publicado: (2000)

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
por: Colombo, N., et al.
Publicado: (2023)

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
por: Monk, Bradley J, et al.
Publicado: (2021)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge
por: Junca, Audelaure, et al.
Publicado: (2020)

Ov2 is a modulator of OvHV-2 RTA mediated gene expression
por: Dry, Inga, et al.
Publicado: (2019)

Nouveau coronavirus (NcOV)
por: Bricaire, François
Publicado: (2013)

Healthcare services access during the COVID-19 pandemic among older people: Paola Bertuccio
por: Bertuccio, P, et al.
Publicado: (2022)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Evaluation of glycoprotein Ov8 as a potential antigen for an OvHV-2-specific diagnostic assay
por: Alhajri, Salim M., et al.
Publicado: (2018)

Deletion of gene OV132 attenuates Orf virus more effectively than gene OV112
por: Yamada, Yumiko, et al.
Publicado: (2022)

Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants
por: Villy, M.-C., et al.
Publicado: (2021)

Tandem Use of OvMANE1 and Ov-16 ELISA Tests Increases the Sensitivity for the Diagnosis of Human Onchocerciasis
por: Shintouo, Cabirou Mounchili, et al.
Publicado: (2021)

Genome Sequences of Cluster K Mycobacteriophages Deby, LaterM, LilPharaoh, Paola, SgtBeansprout, and Sulley
por: Gaballa, Joseph M., et al.
Publicado: (2019)

Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)
por: Nemejcova, Kristyna, et al.
Publicado: (2020)

The NR3B subgroup: an ovERRview
por: Tremblay, Annie M., et al.
Publicado: (2007)

The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice
por: Hess, Jessica A., et al.
Publicado: (2016)

Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
por: Paulino, Eduardo, et al.
Publicado: (2020)

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey
por: Woopen, Hannah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_33o5k3jl9saldmpqr3aq2g8suq